Radiopharm Theranostics Limited American Depositary Shares (RADX) — Cash Flow-to-Debt Ratio
Radiopharm Theranostics Limited American Depositary Shares (RADX) has a Cash Flow-to-Debt Ratio of -0.54x as of December 2025, meaning its operating cash flow of $-22.26 Million could theoretically repay -1% of its total liabilities ($41.19 Million) in one year. Explore how much of Radiopharm Theranostics Limited American's assets are long-term investments to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Radiopharm Theranostics Limited American Depositary Shares Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Radiopharm Theranostics Limited American Depositary Shares across 4 annual periods. Also explore Radiopharm Theranostics Limited American (RADX) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Radiopharm Theranostics Limited American Depositary Shares (2022–2025)
Year-by-year debt coverage analysis for Radiopharm Theranostics Limited American Depositary Shares. For market capitalisation and broader financial context, see Radiopharm Theranostics Limited American stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.84x | $-36.65 Million | $43.61 Million | ▼ -63.4% |
| 2024 | -0.51x | $-22.98 Million | $44.68 Million | ▲ +34.9% |
| 2023 | -0.79x | $-23.20 Million | $29.37 Million | ▼ -62.7% |
| 2022 | -0.49x | $-9.92 Million | $20.42 Million | — |